AbbVie, J&J's Imbruvica wins first pediatric nod, this one for chronic graft-versus-host disease

After nine years on the market and winning 11 FDA approvals, Johnson & Johnson and AbbVie’s Imbruvica has gained its first pediatric nod.

This one is for chronic graft-versus-host disease (cGVHD) and gives children ages 1 to 11 their first treatment option for the life-threatening disorder. The FDA first signed off on Imbruvica’s use for those 12 and older with cGVHD in 2017.